Methods for treating target joints in inflammatory arthritis using AAV vectors encoding a TNF antagonist
AssigneeTargeted Genetics Corporation
InventorPervin Anklesaria
Life of this patent
Estimating the term…
Abstract
The present invention provides methods for treating inflammatory arthritis in an individual, comprising administering to the individual an effective amount of AAV (rAAV) vector comprising a polynucleotide encoding a pro-inflammatory cytokine antagonist, wherein the individual is being treated systemically with a polypeptide pro-inflammatory antagonist but still has one or more persistently symptomatic joints.
Claims21
A method for treating inflammatory arthritis in an individual, comprising administering to a persistently symptomatic joint of the individual an effective amount of an recombinant AAV (rAAV) vector comprising a polynucleotide encoding a fusion polypeptide comprising an extracellular domain of tumor necrosis factor receptor (TNFR) and a constant domain of an immunoglobulin molecule, wherein the individual has been treated systemically with an art recognized effective amount of a polypeptide TNF-α antagonist but still has one or more persistently symptomatic joints despite the systemic polypeptide TNF-α antagonist treatment.
A method for enhancing the treatment effect of a polypeptide TNF-α antagonist in an individual, comprising administering to a persistently symptomatic joint of the individual an effective amount of a recombinant AAV (rAAV) vector comprising a polynucleotide encoding a fusion polypeptide comprising an extracellular domain of tumor necrosis factor receptor (TNFR) and a constant domain of an immunoglobulin molecule, in conjunction with the polypeptide TNF-α antagonist, wherein the individual has been treated systemically with the polypeptide TNF-α antagonist but still has one or more persistently symptomatic joints despite the systematic polypeptide TNF-α antagonist treatment.
Dependencies are inferred from the claim text.